Favrille Announces Status of Patient Enrollment in Registration Trial

Favrille has enrolled 220 eligible patients into its Phase III registration clinical trial testing its lead product candidate, FavId, following Rituxan in patients with follicular non-Hodgkin's lymphoma.

This enrollment represents approximately 65 percent of the 342 randomized, evaluable patients required to be enrolled in the trial. As originally projected, the company expects to complete enrollment on schedule by year end.